

A

Please type a plus sign (+) inside this box → ☐PTO/SB/05 (12/97)
Approved for use through 09/30/00. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.UTILITY
PATENT APPLICATION
TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 11002-143

Total Pages 52

First Named Inventor or Application Identifier

Stephen R. ASH

Express Mail Label No. EM065139349US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☐ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification (Copy) [Total Pages 41]
(preferred arrangement set forth below)
- Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 USC 113) [Total Sheets 3]
4. Oath or Declaration [Total Pages 3]
- a. ☐ Newly executed (original or copy)
- b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
(Note Box 5 below)
- i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
5. ☒ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- a. ☐ Computer Readable Copy
- b. ☐ Paper Copy (identical to computer copy)
- c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☒ Small Entity ☒ Statement filed in prior application, Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Other:

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: 08 869,331

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Labelor ☒ Correspondence address below

(Insert Customer No. or Attach bar code label here)

NAME

Gregory B. Coy, Esq.

Woodard, Emhardt, Naughton, Moriarity & McNett

ADDRESS

Bank One Center/Tower

111 Monument Circle, Suite 3700

CITY

Indianapolis

STATE

IN

ZIP CODE

46204-5137

COUNTRY

USA

TELEPHONE

317-634-3456

FAX

317-637-7561

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:)
)
Stephen R. ASH)
)
Serial No.: 08/869,331)
)
Filed: June 5, 1997)
)
METHOD FOR IRON DELIVERY TO A)
PATIENT BY TRANSFER FROM)
DIALYSATE) August 14, 1998

Before the Examiner
Leonard Schenkman
Group Art Unit 1614

COPY

VERIFICATION OF
SMALL ENTITY STATUS

BOX ISSUE FEE
Assistant Commissioner for Patents
Washington, DC 20231

Sir:

The Applicant tenders herewith a fresh Statement Claiming Small Entity Status for Independent Inventor, for Small Business Concern as to HemoCleanse, Inc., and a new Statement Claiming Small Entity Status for Small Business Concern as to R&D

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on August 14, 1998.

GREGORY B. COY
Name of Registered Representative


G. B. Coy
Signature

August 14, 1998
Date of Signature

Laboratories, Inc. While small entity status has not changed for this case, a third party now owns rights in the invention. Therefore, the basis for small entity status has changed and is supported by the enclosed statements.

Respectfully submitted

COPY

By: 
Gregory B. Coy
Reg. No. 40,967
Woodard, Emhardt, Naughton,
Moriarty & McNett
Bank One Center/Tower
111 Monument Circle, Suite 3700
Indianapolis, Indiana 46204-5137
(317) 634-3456

**STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(b))--INDEPENDENT INVENTOR**

Docket Number (Optional)

11002-29

Applicant, Patentee, or Identifier: Stephen R. ASH

Application or Patent No.: 08/869,331

Filed or Issued: June 5, 1997

Title: METHOD FOR IRON DELIVERY TO A PATIENT BY TRANSFER FROM DIALYSATE

As a below named inventor, I hereby state that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees to the Patent and Trademark Office described in:

- ☐ the specification filed herewith with title as listed above.
☒ the application identified above.
☐ the patent identified above.

I have not assigned, granted, conveyed, or licensed, and am under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☐ No such person, concern, or organization exists.
☒ Each such person, concern, or organization is listed below.

HemoCleave, Inc.

2700 Kent Avenue

West Lafayette, TN 47906

R & D Laboratories, Inc.

4640 Admiralty Way, Suite 710

Marina Del Ray, CA 90292

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

Stephen R. ASH

NAME OF INVENTOR

NAME OF INVENTOR

NAME OF INVENTOR

Signature of inventor

Signature of inventor

Signature of inventor

Date

Date

Date

**STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(c))--SMALL BUSINESS CONCERN**

Docket Number (Optional)
11002-29

Applicant, Patentee, or Identifier: Stephen R. ASH
Application or Patent No.: 08/869,331
Filed or Issued: June 5, 1997
Title: METHOD FOR IRON DELIVERY TO A PATIENT BY TRANSFER FROM DIALYSATE

I hereby state that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN HemoCleanse, Inc.

ADDRESS OF SMALL BUSINESS CONCERN 2700 Kent Avenue
West Lafayette, IN 47906

I hereby state that the above identified small business concern qualifies as a small business concern as defined in 13 CFR Part 121 for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time, or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby state that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

- ☐ the specification filed herewith with title as listed above.
☒ the application identified above.
☐ the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern, or organization having rights in the invention must file separate statements as to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

- Each person, concern, or organization having any rights in the invention is listed below:
☐ no such person, concern, or organization exists.
☒ each such person, concern, or organization is listed below.

R & D Laboratories, Inc.

Separate statements are required from each named person, concern or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

NAME OF PERSON SIGNING Robert B. Truitt

TITLE OF PERSON IF OTHER THAN OWNER President

ADDRESS OF PERSON SIGNING 2700 KENT AVE, N. LAFAYETTE, IN 47906

SIGNATURE Robert B. Truitt DATE 8/5/98

STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(c))--SMALL BUSINESS CONCERN

Docket Number (Optional)
11002-29

Applicant, Patentee, or Identifier: Stephen R. ASH
Application or Patent No.: 08/869,331
Filed or Issued: June 5, 1997
Title: METHOD FOR IRON DELIVERY TO A PATIENT BY TRANSFER FROM DIALYSATE

I hereby state that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN R & D Laboratories, Inc.

ADDRESS OF SMALL BUSINESS CONCERN 4640 Admiralty Way, Suite 710
Marina Del Ray, CA 90292

I hereby state that the above identified small business concern qualifies as a small business concern as defined in 13 CFR Part 121 for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time, or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby state that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

- ☐ the specification filed herewith with title as listed above.
☒ the application identified above.
☐ the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern, or organization having rights in the invention must file separate statements as to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

- Each person, concern, or organization having any rights in the invention is listed below:
☐ no such person, concern, or organization exists.
☒ each such person, concern, or organization is listed below.

Hemocleanse, Inc.

Separate statements are required from each named person, concern or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

NAME OF PERSON SIGNING Rhoda Makoff

TITLE OF PERSON IF OTHER THAN OWNER PRESIDENT / CEO

ADDRESS OF PERSON SIGNING 4640 ADMIRALTY WY MAR CA 90292

SIGNATURE Rhoda Makoff DATE 8/10/98

2-0712U

METHOD FOR IRON DELIVERY TO A PATIENT BY
TRANSFER FROM DIALYSATE

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to methods and compositions for efficiently delivering iron to a patient. More particularly, the present invention is concerned with dialysates and dialysate concentrates, and methods for delivering to a patient via dialysis a composition comprising ionic iron complexed with one or more anions. An iron complex selected according to the invention is non-polymeric; soluble in an aqueous medium; chemically stable, thereby preventing the dissociation of iron ions from the anions under conditions according to the invention; and can be well absorbed by blood and the living body.

Description of Related Art

Iron is a metal which is an essential requirement for tissue growth in humans and many animals. Therefore, an adequate supply of iron is critical to their survival and well-being. Although there is normally an ample amount of iron in the diet, the level of absorption of iron from food is generally low and, therefore, the supply of iron to the body can easily become critical under a variety of conditions. For example, iron is a necessary ingredient in the production of

"Express Mail" label number EM0651393492LS
Date of Deposit August 25, 1998
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37CFR § 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.
Deanna S. Hessler
Signature of person mailing paper or fee

red blood cells, and a lack of iron may quickly lead to anemia. Iron deficiency anemia is commonly encountered, for example, in pregnancy and may also present a problem in the newly born. Moreover, in certain pathological conditions there is a maldistribution of body iron leading to a state of chronic anemia. This is seen in chronic diseases such as rheumatoid arthritis, certain haemolytic diseases and cancer.

Anemia is also uniformly present in patients with end stage renal disease (ESRD). The major cause of this anemia is the deficient production of erythropoietin hormone (EPO) by the native kidneys. EPO stimulates the bone marrow to produce red cells, and when EPO is deficient, patients invariably become anemic. To counter the anemia of ESRD patients, recombinant EPO (which is very expensive) may be administered subcutaneously or intravenously. Recombinant EPO can effectively increase the hematocrit of patients with adequate iron stores, but the increased rate of production of new red cells quickly depletes body iron stores and, when this occurs, EPO becomes completely ineffective. As such, the delivery of iron to an ESRD patient is critical to his or her treatment. Methods in the prior art for delivering iron to a patient, such as an ESRD patient, have proven largely impractical and unsatisfactory, and there is a great need for improved methods of iron delivery.

It is well known that iron is very difficult to assimilate into the cells of a living organism and when an iron deficiency exists, oral iron supplements in relatively large doses are commonly administered wherein the iron may be in a wide variety of forms, i.e., usually as various organic and inorganic salts. Iron compositions which have been previously administered orally include, for example, ferrous gluconate, ferrous citrate, ferrous sulfate, ferrous fumarate and ferric-polysaccharide complexes. As a specific example of a condition where oral iron delivery is common, ESRD patients are typically directed to take oral iron tablets when EPO is started, as discussed above.

Oral iron administration, however, has several disadvantages. Patient noncompliance, gastrointestinal side effects, interactions with other oral medications and very poor absorption in ESRD patients markedly limit its effectiveness. For example, patients often stop taking these medications because of side effects associated therewith, such as constipation and gastric irritation. Additionally, these oral iron preparations cause a patient's stools to turn black, thereby making it difficult for caregivers to detect gastrointestinal bleeding during iron therapy. It is believed that these problems are all related to the administration of relatively high dosage levels of oral compounds due to the low level of iron uptake by the body, and these high doses are thought to also cause siderosis of the gut wall.

1

To overcome the above-described problems with oral delivery of iron, a great deal of effort has been directed to developing iron delivery methods wherein iron-containing compositions are delivered parenterally, either by intravenous or intramuscular injection. In this regard, it is currently widely believed that compositions used for non-oral iron administration must be in macromolecular form. This mindset is based upon the belief that the use of macromolecules eliminates the problem of osmolarity in the case of intramuscular injection, and, in the case of intravenous injection, the belief that macromolecular compositions are required to ensure that free iron is not introduced into the blood. Since iron is slowly freed from such macromolecules by the action of metabolism, and then bound by transferrin in the blood as it slowly becomes available, administration of iron in macromolecular forms is presently thought to be the only viable option with respect to intravenous administration techniques.

063350-ETHETON

With respect to intravenous administration, iron-dextran (INFED®), which may be obtained from Schein Pharmaceuticals, Phoenix, Arizona, is commonly administered intravenously to ESRD patients to increase iron stores, with about 100-200mg injected each successive dialysis until about 1000mg are administered. Iron dextran is a macromolecule having a high average molecular weight ranging generally between about 100,000 and about 200,000. However, iron dextran occasionally

causes severe allergic reactions, fever and rashes during injection and must therefore be administered slowly and after a small test dose. Ferric gluconate is another macromolecular iron complex for intravenous administration, and is relatively free of symptoms. However, each of these intravenous iron preparations is very expensive and requires a great deal of time and skill for administration. The large expense related to these intravenous preparations is associated in part with the necessity for sterilization of the injectant. Additionally, intravenous administration requires venous access, which is available during hemodialysis, but not commonly available in peritoneal dialysis patients. Finally, only about half of iron in iron dextran is bio-available after intravenous injection for red cell production. The fate of the rest is unknown.

With respect to intramuscular injection, iron dextrans and iron dextrans may be administered intramuscularly; however, as a result of their high molecular weights, absorption in the human or animal body is incomplete. Furthermore, the administration of these compositions intramuscularly is painful and often results in an undesirable discoloration at the injection site. Alternatively, U.S. Patent No. 3,686,397 to Muller teaches an iron preparation for intramuscular injection which comprises a nonionic complex of trivalent iron supplied a ferric hydroxide with a complex forming agent consisting of

sorbitol, gluconic acid and certain oligosaccharides (polyglucoses) in certain proportions and amounts. Other macromolecular iron preparations which may be administered via intramuscular injection are taught in U.S. Patent No. 5,177,068 to Callingham et al., U.S. Patent No. 5,063,205 to Peters et al., U.S. Patent No. 4,834,983 to Hider et al. and U.S. Patent No. 4,167,564 to Jenson. Many preparations, such as that taught in the Jenson patent, may be administered parenterally either by intramuscular or intravenous injection.

Recently, it has been proposed that iron may be administered to a mammal by intraperitoneal delivery of macromolecular iron dextran. It has been found that only about half of the iron delivered intraperitoneally in this form is bioavailable, passing to the blood and then to the reticulo-endothelial system and bone marrow, where it is incorporated into red cells. It appears that about 50% of the iron dextran is stored permanently in the body and is not available for red cell production. There is evidence that macrophages near the peritoneum pick up iron-dextran and store it within themselves, creating an abnormal physical condition which could lead to abnormal membrane changes in the peritoneum.

In light of this background, there is a great need in the art for improved methods for delivering iron to a patient. The present invention addresses the problems in the prior art by providing methods and compositions for delivering iron by

transfer of a low molecular weight (non-polymeric) iron complex from dialysate. Inventive methods are surprisingly effective in light of conventional thought, which teaches that complexes selected according to the invention do not have sufficient solubility to be useful in this manner. Further, it is widely believed that soluble iron complexes are unacceptable iron delivery agents, this belief being based upon a fear of the toxicity of free iron in blood.

The present inventor has discovered that iron complex compositions selected in accordance with the invention are tightly complexed and are highly soluble, and can thereby be safely administered to a patient using dialysis with minimal staff effort and very little risk. This high solubility also advantageously allows an inventive complex to be included in dialysate concentrates, which are described in greater detail herein. For hemodialysis applications, the iron can be added to a dialysate or a concentrate, just as other solutes, in "clean" form and need not be sterilized. For peritoneal applications, the iron composition can be sterilized.

SUMMARY OF THE INVENTION

The present invention provides methods and compositions for delivering iron to an iron-deficient patient. More particularly, the invention relates to delivering to a patient via dialysis a composition comprising ionic iron complexed with one or more anions, wherein the complex is non-polymeric; soluble in an aqueous medium; chemically stable, thereby preventing the dissociation of iron ions from the anions under conditions according to the invention; and can be well absorbed by blood and the living body.

According to one specific aspect of the invention, there is provided a method for performing dialysis with a complex of one or more divalent or trivalent iron ions and one or more anions, the complex having a molecular weight of less than about 50,000 and preferably being non-polymeric. This method of delivering iron to a patient comprises providing an aqueous dialysate having the complex dissolved therein, and dialyzing a patient with the dialysate to increase the level of iron in the patient's blood. Inventive methods achieve this advantageous result without introducing free iron into the blood. A preferred anion according to one aspect of the invention is an organic anion.

According to another aspect of the invention, there is provided a method for delivering iron to blood which comprises passing blood against a first side of a membrane and passing

against a second side of the membrane an aqueous solution having dissolved therein an iron complex comprising one or more iron ions and one or more anions, the complex having a molecular weight of less than about 12,000; wherein the membrane is permeable to the complex and wherein the complex is delivered to the blood.

According to another aspect of the invention, there is provided a method for increasing the level of iron in a patient's blood by introducing a dialysate into a patient's peritoneal cavity, the dialysate comprising a non-polymeric complex of one or more divalent or trivalent iron ions and one or more anions, the complex having a molecular weight of less than about 50,000.

In another aspect of the invention, there is provided a dialysate composition having dissolved therein sodium, magnesium, calcium, potassium, chloride, acetate, bicarbonate and an iron complex having a molecular weight of less than about 50,000. An inventive dialysate comprises from about 130 to about 150 mEq/L sodium, from about 0.4 to about 1.5 mEq/L magnesium, from about 2 to about 4 mEq/L calcium, from about 1 to about 4 mEq/L potassium, from about 90 to about 120 mEq/L chloride, from about 3 to about 5 mEq/L acetate, from about 30 to about 40 mEq/L bicarbonate and from about 1 to about 250 $\mu\text{g}/100\text{ml}$ of iron as an iron complex having a molecular weight of less than about 50,000. Also provided is a

dialysate concentrate, prepared for subsequent dilution to a suitable concentration for use as a dialysate, preferably having a concentration about 30 to about 40 times greater than the concentration of the desired dialysate.

It is an object of the present invention to provide improved methods for administering iron to a patient, especially a patient suffering from chronic anemia and end stage renal disease.

Another object of the invention is to provide methods whereby conventional hemodialysis techniques may be used to deliver iron to a patient without the need to sterilize the iron-containing composition prior to administration.

It is also an object of the invention to provide methods for delivering iron to peritoneal dialysis patients by providing a dialysate which includes sterile non-polymeric iron complexes according to the invention.

Additionally, it is an object of the invention to provide dialysate compositions which may be advantageously used to deliver iron to a patient by a wide variety of dialysis techniques and concentrates thereof.

Further objects, features, and advantages of the present invention shall become apparent from the detailed drawings and descriptions provided herein.

BRIEF DESCRIPTION OF THE DRAWINGS

Although the characteristic features of this invention will be particularly pointed out in the claims, the invention may be better understood by referring to the following descriptions taken in connection with the accompanying drawings forming a part hereof.

FIG. 1 is a plot of iron concentration ($\mu\text{g}/\text{dl}$) in plasma versus elapsed time in minutes in the experiment described in Example 1. The horizontal line at $234\mu\text{g}/\text{dl}$ represents the capacity by transferrin in plasma to bind soluble iron, and the horizontal line at $125\mu\text{g}/\text{dl}$ represents the concentration of iron in the dialysate described in Example 1.

FIG. 2 is a plot of absorbance of plasma at 420 and 585 nm versus elapsed time in minutes, obtained as described in Example 2.

FIG. 3 is a plot of optical absorbance of ferrous gluconate at high concentration ($100\text{ mg}/\text{dl}$) versus wavelength (nm), taken for the blood-leak detector experiment described in Example 3.

DESCRIPTION OF THE PREFERRED EMBODIMENT

For the purposes of promoting an understanding of the principles of the invention, reference will now be made to the preferred embodiments and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended. Any alterations and further modifications in the described invention, and any further applications of the principles of the invention as described herein are contemplated as would normally occur to one skilled in the art to which the invention relates.

The present invention overcomes problems in the prior art associated with delivering iron to a patient. Iron delivery" according to the invention is accomplished by providing a dialysate composition comprising a iron complex which is soluble in an aqueous medium and delivering the complex to a patient using conventional dialysis techniques. An "iron complex," as used herein, is intended to designate a composition comprising one or more iron ions complexed with one or more suitable anions and having a molecular weight of less than about 50,000. Inventive iron complexes are preferably non-polymeric .

This invention, therefore, relates to surprisingly efficacious methods for delivering iron by providing a dialysate, the dialysate advantageously being prepared either

by on-site preparation or by diluting a pre-made dialysate concentrate and the dialysate having dissolved therein, among other solutes, a low molecular weight non-polymeric iron complex; and dialyzing a patient therewith using one of a wide variety of dialysis techniques. Inventive methods are useful for delivering iron to a patient in readily-available form and, since iron complexes according to the invention are relatively tightly bound, they may advantageously be delivered to a patient without risk of introducing free iron into the blood. It is contemplated that various compositions, compositional ratios, procedures, and processes described in connection with the present invention could be altered or substituted as would occur to those skilled in the art without departing from the spirit of the invention. It is believed that inventive methods may advantageously be used in conjunction with dialysis techniques currently in wide use, as well as improvements thereof, and with dialysis techniques yet to be developed. It is anticipated that the present invention may find particularly advantageous use in hemodialysis procedures and intraperitoneal dialysis procedures.

With regard to specific examples of dialysis techniques, it is well known that conventional hemodialysis procedures may be performed in free-standing treatment centers, although they may also be provided in a hospital or performed by the patient at home. Conventional hemodialysis circuits have two fluid

pathways: the blood circuitry and the dialysate circuitry. The blood circuitry conventionally comprises a 15-gauge needle for access to the circulation (usually through an arteriovenous fistula created in the patient's forearm), lengths of plasticized polyvinyl chloride tubing (including a special segment adapted to fit into a peristaltic blood pump), the hemodialyzer itself, a bubble trap and an open mesh screen filter, various ports for sampling or pressure measurements at the blood outlet, and a return cannula. Access to the circulation may alternatively be made at a single access point using a double-lumen catheter. Components of the blood side circuit are supplied in sterile and nonpyrogenic condition. The dialysate side typically comprises a machine capable of (1) proportioning out glucose and electrolyte concentrates with water to provide a dialysate of appropriate composition; (2) pulling dialysate past a restrictor valve and through the hemodialyzer at subatmospheric pressure; and (3) monitoring temperature, pressures, and flow rates.

During treatment the patient's blood is typically anticoagulated with heparin. Typical blood flow rates are about 200-350 ml/min and dialysate flow rates are usually set at about 500 ml/min. A dialysate volume of about 120-200 liters is typically used per dialysis treatment. Simple techniques have been developed to prime the blood side with sterile saline prior to use and to return to the patient nearly

all the blood contained in the extracorporeal circuit after treatment. Whereas most mass transport occurs by diffusion, circuits are typically operated with a pressure on the blood side, which may be 100-500 mmHg higher than on the dialysate side. This provides an opportunity to remove 2-4 liters of fluid along with solutes in a single treatment. Higher rates of fluid removal are technically possible but physiologically unacceptable. Hemodialyzers must be designed with high enough hydraulic permeabilities to provide adequate fluid removal at low transmembrane pressure but not so high that excessive water removal will occur in the upper pressure range.

Although other geometries may be employed, one preferred hemodialyzer format is a "hollow fiber" hemodialyzer about 25 cm in length and 5 cm in diameter, resembling the design of a shell and tube heat exchanger. Blood enters this type of hemodialyzer at an inlet manifold, is distributed to a parallel bundle of capillary tubes (typically potted together with polyurethane), and exits at a collection manifold. Dialysate flows countercurrent in an external chamber. The shell is typically made of an acrylate or polycarbonate resin. Devices typically contain about 6000-10,000 capillaries, each with an inner diameter of about 200-250 microns and a dry wall thickness as low as about 10 microns. The total membrane surface area in commercial dialyzers typically varies from about 0.5 to about 1.5 m², and units can be mass-produced at a relatively low cost.

Although a specific hemodialysis set-up is described in detail above, it is well understood that a wide variety of hemodialysis devices may be advantageously used in accordance with the invention. Examples of alternate hemodialysis devices and methods suitable for use according to the invention are set forth in U.S. Patent No. 5,277,820 to Ash; U.S. Patent No. 4,661,246 to Ash; U.S. Patent No. 4,581,141 to Ash; U.S. Patent No. 4,348,283 to Ash; U.S. Patent No. 4,071,444 to Ash et al.; U.S. Patent No. 3,734,851 to Matsumura; U.S. Patent No. 4,897,189 to Greenwood et al.; U.S. Patent No. 4,267,041 to Schael; U.S. Patent No. 4,118,314 to Yoshida; U.S. Patent No. 3,989,625 to Mason; and U.S. Patent No. 3,962,075 to Fialkoff et al. These patents are hereby incorporated herein by reference.

In a hemodialysis treatment, as discussed above, blood is removed from the body, propelled through a closed system of membranes, and returned to the body, while on the other side of the membranes is an aqueous dialysis fluid. These membranes are semipermeable, allowing small molecules to pass through, but retaining larger molecules such as proteins, as well as cellular blood elements. Uremic substances, being small molecules, will pass through the membranes as long as the concentration of these substances is kept low in the dialysis fluid, or dialysate, on the other side of the membrane. The

aqueous medium so used must be prior treated to remove trace elements (which would otherwise pass back across the membrane into the blood), must be supplemented with electrolytes and glucose, and must then be warmed to blood temperature. The electrolytes are added to the dialysate so as to prevent excessive ion removal (i.e., Mg^{++} , K^+ , Na^+ , Cl^- and HCO_3^-). Calcium ions should also be in slight excess in the dialysate so as to cause addition of calcium to the patient's blood, as the total body calcium in kidney failure patients is often low, leading to stimulation of parathyroid hormone, which is detrimental to the patient's health.

In one preferred aspect of the present invention, a non-polymeric iron complex is used according to the invention in conventional extracorporeal hemodialysis techniques by providing a dialysate, for example, as described above, having the iron complex dissolved therein to a predetermined concentration. An iron complex to be dissolved into dialysate for hemodialysis must be "clean," but need not be sterile, as is the case for other solutes in a dialysate. This provides a substantial advantage over prior methods of iron delivery to a patient by intramuscular or intravenous injection, both of which necessitate that the iron preparation be sterilized prior to injection. The dialysate, having a clean iron complex dissolved therein will deliver the iron complex to the blood during dialysis by diffusion, at a rate automatically

responding to the blood plasma concentration, just as the concentrations of other solutes (such as, for example, sodium, potassium, glucose, bicarbonate, magnesium, calcium and chloride) are adjusted in dialysate to assure proper plasma levels in a patient. In the case of inventive iron complexes, however, it appears that blood proteins are binding the complex, thereby removing the complex from the plasma and maintaining a concentration gradient between the dialysate and the blood. Basis for this theory is found in Example 1 and Fig. 1, where it is shown that the total amount of ferrous gluconate transferred to blood is higher than that expected based upon simple concentration gradient analysis. Thus, transfer of an inventive iron complex to the blood will continue until the level of free iron complex in the plasma reaches the same concentration as the iron complex dissolved in dialysate.

Turning now to an alternate dialysis technique, another type of dialysis with which inventive methods may be advantageously used is continuous ambulatory peritoneal dialysis (CAPD), also referred to herein interchangeably as "peritoneal dialysis" or "intraperitoneal dialysis." In this type of dialysis, approximately 2 liters of a sterile, nonpyrogenic, and hypertonic solution of glucose and electrolytes are instilled via gravity flow into the peritoneal cavity of a patient through an indwelling catheter, typically 4

times per day. Intraperitoneal fluid partially equilibrates with solutes in the plasma, and plasma water is ultrafiltered due to osmotic gradients. After about 4-5 hours, except at night where the exchange is lengthened to about 9-11 hours to accommodate sleep, the peritoneal fluid is drained and the process repeated. Patients may perform the exchanges themselves in about 20-30 minutes, for example at home or in the work environment, after a training cycle which usually lasts about 1-2 weeks. Alternatively, automated peritoneal dialysis (APD) may be used, in which case about 10-15 liters of dialysate are automatically exchanged overnight and 2 liters remain in the peritoneal cavity during the day for a "long dwell" exchange.

Access to the peritoneum is usually via a double-cuff Tenckhoff catheter, essentially a 50-100 cm length of silicone tubing with side holes at the internal end, a dacron mesh flange at the skin line, and connector fittings at the end of the exposed end. A wide variety of variations exist, however, and may advantageously be used in accordance with the invention. Most are implanted in a routine surgical procedure requiring about 1 hour and are allowed to heal for about 1-2 weeks prior to routine clinical use. Sterile and nonpyrogenic fluid is commonly supplied in 2 liter containers fabricated from dioctyl phthalate plasticized polyvinyl chloride. The formulation is essentially potassium-free lactated Ringers to

which has been added from about 15-42.5 grams/liter of glucose (dextrose monohydrate). The solution is buffered to a pH of about 5.1-5.5, since the glucose would caramelize during autoclaving at higher pH levels.

Several different exchange protocols may be used in a peritoneal dialysis procedure. In one conventional design, the patient simply rolls up the empty bag after instillation and then drains into the same bag following exchange. The bag filled with drain fluid is disconnected and a fresh bag is reconnected. Patients are trained to use aseptic technique to perform the connect and disconnect. Many aids have been developed to assist in minimizing breaches of sterility including enclosed ultraviolet-sterilized chambers and heat splicers. More recent approaches, known as the "O" set and "Y" set or more generically as "flush before fill" disconnect, invoke more complex tubing sets to allow the administration set to be flushed (often with antiseptic) prior to instillation of dialysate and generally permit the patient to disconnect the empty bag during the dwell phase. Initial reports of the success of these protocols in reducing peritonitis were regarded with skepticism, but improvement over earlier systems has now been documented in well-designed and carefully controlled clinical trials.

Iron complexes selected in accordance with the invention may also be administered to a patient from dialysate

intraperitoneally, for example, as described above. While dialysates used for intraperitoneal dialysis must be sterilized prior to use, this aspect of the invention also provides an excellent manner in which to introduce iron complexes into a patient's blood in an advantageous form. In intraperitoneal dialysis techniques, just as in hemodialysis techniques, a smaller iron complex will move more readily from the dialysate into the patient's blood than will a larger complex.

While the term "dialysate" is used interchangeably in various contexts, for instance, with respect to hemodialysis and with respect to peritoneal dialysis, it is readily understood by a skilled artisan that a variety of solutes and concentrations of solutes may be used with respect to various dialysis techniques, and also may vary with respect to the particular needs of a given patient. Because an iron complex selected for use according to the invention is absent in native blood, its presence in dialysate results in diffusion from the dialysate into the blood. This diffusion is augmented in preferred aspects of the invention by the apparent binding of the iron complex to plasma proteins.

It should be pointed out that the term "complex" may have alternate meanings in various contexts in the related art and, therefore, clarification of its meaning for purposes of describing the invention is in order. At one level, the term "complex" may be used to describe the association between two

or more ions to form a relatively low molecular weight non-polymeric composition which exists singly under a given set of conditions. This type of complex may be referred to as a "primary complex," and this is the manner in which the term is to be used herein. As such, the term "primary complex" is used interchangeably herein with the term "complex" for purposes of describing the invention. An alternate manner in which this term is used in the related field is to describe the association or agglomeration of a plurality of primary complexes into a large macromolecule, or "secondary complex." For purposes of simplicity, these agglomerates are referred to herein as macromolecules, and are not considered "complexes" as the term is used to describe the invention.

As an example of the above distinction, ferrous gluconate is a composition comprising divalent iron ions and gluconate anions. A divalent iron ion and two gluconate anions form a primary complex of relatively low molecular weight (about 450 Daltons) and primary complexes of this type do not become agglomerated into macromolecules when dissolved into an aqueous medium. Ferrous gluconate, therefore, is a composition which falls within the scope of the term "complex" herein. Ferric gluconate, however, does not exist as such a complex because primary complexes of trivalent iron ions and gluconate anions agglomerate together to form very large macromolecules (commonly having a molecular weight of between about 100,000

and 600,000 Daltons). As such, iron complexes according to the invention are identified by selecting a combination of one or more iron ions (either divalent or trivalent) and one or more anions which interact to form primary complexes, but do become agglomerated into macromolecules.

As such, the present invention provides dialysate compositions, and methods of using them, which comprise a primary iron complex of one or more divalent or trivalent iron ions and one or more anions described herein; which does not become associated or agglomerated to form a macromolecule; which is soluble in an aqueous medium; and which has a molecular size and, correspondingly, a molecular weight, which imparts advantageous properties with respect to diffusion of the complex through a dialysis membrane.

With respect to solubility, the solubility of a given iron complex according to the present invention must be such that the concentration of the complex in a dialysate solution may be achieved which enables the desired level of iron delivery to the patient. While conventional belief in the relevant field is that complexes of the invention would not be sufficiently soluble in an aqueous medium to find advantageous use, the present inventor has discovered that preferred inventive complexes are highly soluble.

The particular concentration of iron complex to be dissolved in a dialysate according to the present invention is

dependent upon the amount of iron desired to be transferred to the patient's blood. For example, the amount of iron desired to be transferred in the case of an anemic patient is associated with the known blood building requirements of the patient. In other words, to determine the desired concentration of the iron complex in the dialysate, it is first calculated how much iron the patient needs for building blood cells. The complex will transfer to the patient at a controlled, definable rate, since the iron complex does not exist naturally in the blood. As is readily understood by one skilled in the art, a higher concentration of iron complex would be needed in peritoneal dialysis techniques than that which would be needed in extracorporeal hemodialysis techniques due to differing rates of diffusion with respect to the respective membranes and due to the lower daily volume of dialysate used in peritoneal dialysis. Preferred concentrations in a given situation may be readily determined by a skilled artisan with minimal experimentation.

In a preferred aspect of the invention, iron complexes selected for use are sufficiently soluble in aqueous media to be advantageously included in a wide variety of formulations to make dialysate concentrates. As used herein, the term "concentrate" is intended to designate a solution wherein the solutes are dissolved therein at concentrations much greater (commonly about 30-40 times greater) than a desired dialysate

concentrate. A dialysate concentrate, therefore, has a volume 0-40 times less than the actual dialysate and may therefore be pre-mixed and advantageously shipped and handled much more readily. At the location of a dialysis procedure, a concentrate is diluted to the proper volume, commonly in the dialysis instrument itself, thereby providing a dialysate having suitable solute concentrations for the particular use.

The high concentration of solutes in a dialysate concentrate results in a reduced amount of water which is available to dissolve additional solutes. Therefore, the most preferred iron complexes used in accordance with the invention are highly soluble. The use in the art of dialysate concentrates is apparently an additional factor which has engendered the belief that iron complexes, such as those selected in accordance with the invention, do not have sufficient solubility to be used as described herein. In contravention of this belief, the present inventor has discovered, for example, that ferrous gluconate is stably soluble in such a concentrate at levels over 8 grams per 100 ml (dl), thus providing an iron concentration of about 1 gram per 100 ml. As is readily ascertainable by one skilled in the art, this would result in an iron concentration in dialysate of approximately 30 mg (30,000 μ g) per 100 ml after a 35:1 dilution.

An iron complex contemplated for use according to the present invention comprises one or more divalent or trivalent

iron ions relatively tightly bound to one or more anions to form a low molecular weight iron complex. As used herein, "relatively tightly bound" is intended to mean that the iron ion or ions and the anion or anions will not readily become dissociated under conditions of the present invention to yield free iron ions. The anion may be a natural or a synthetic molecule and may be either organic or inorganic, so long as it forms a primary complex with divalent or trivalent iron ions according to the present invention, but does not ultimately become associated into a macromolecule and so long as the anion is biocompatible. It is important that the iron ion and the anion remain tightly bound under relevant conditions because an overabundance of free iron ions in a dialysate and, as a result, in a patient's blood, may cause hemolysis and, if extreme, may cause death.

The anion of an iron complex selected in accordance with the invention is preferably a multi-polar anion, including for example a divalent or trivalent anion (e.g. di- or tricarboxylic acids (preferably aliphatic) having up to about 10 carbon atoms, optionally also substituted with one or more polar groups such as hydroxyl groups); or a monovalent anion which has additional polar substituents (such as hydroxyl groups) and which is readily complexed with iron ions, such as monohydroxycarboxylic or polyhydroxycarboxylic acids, typically having up to about 10 carbon atoms, especially aliphatic acids of this type such as gluconic acid. It is contemplated that

suitable anions for iron complexes of the invention include, for example, gluconate, sulfate, fumarate, citrate and succinate. It is not intended, however, that this list be limiting, and it is within the purview of a skilled artisan to identify anions which form suitable iron complexes for advantageous use according to the invention.

The term "low molecular weight iron complex" is intended to designate an iron complex having a size useful for passing through dialysis membranes. As such, iron complexes selected according to the invention preferably have a molecular weight of less than about 50,000 and are preferably non-polymeric. This designation is intended to distinguish iron complexes selected according to the invention from large polymeric compositions and compositions in which primary complexes have become associated with one another to form macromolecules, as discussed above. This molecular weight limitation ensures that iron complexes used according to the present invention are of a size which will pass a wide variety of dialysis membranes used in a wide variety of dialysis methods. It is readily understood by a skilled artisan that many iron complexes selected according to the invention may be advantageously used in both hemodialysis techniques and in intraperitoneal dialysis techniques. Some iron complexes, however, such as those having a molecular weight greater than about 12,000, may not diffuse through many membranes used in hemodialysis to a suitable degree, but may nevertheless be advantageously used in intraperitoneal dialysis techniques.

With regard to intraperitoneal dialysis, it is expected that an iron complex having a molecular weight greater than about 50,000 will not be transported to the patient's blood. In a preferred aspect of the invention, therefore, the iron complex to be used for intraperitoneal dialysis has a molecular weight of less than about 50,000, preferably less than about 25,000, more preferably less than about 12,000 and most preferably less than about 5000.

With regard to extracorporeal hemodialysis methods, it is preferred that the iron complex have a molecular weight of less than about 12,000. More preferably, the iron complex has a molecular weight of less than about 5,000 and most preferably less than about 2,500. It is to be understood that the lower the molecular weight of the iron complex and, correspondingly, the smaller the iron complex, the faster the iron complex may be incorporated into a patient's blood.

Complexes selected for use according to the invention may be identified, therefore, by their molecular weight, by their degree of solubility in an aqueous medium and by their ability to remain tightly complexed under conditions of the invention. In this regard, a useful way to determine whether an iron-containing composition falls within the scope of the invention, is to introduce it into water and, using techniques well known to those skilled in the art, to test levels of solubility and to determine whether the complex becomes dissociated in solution.

According to another aspect of the invention, there is provided a dialysate composition having dissolved therein sodium, magnesium, calcium, potassium, chloride, acetate, bicarbonate and an iron complex having a molecular weight of less than about 50,000. In certain preferred embodiments of the invention, the dialysate may also optionally include dextrose, a sorbent and/or a surfactant. Preferably, the dialysate composition comprises from about 130 to about 150 mEq/L sodium, from about 0.4 to about 1.5 mEq/L magnesium, from about 2 to about 4 mEq/L calcium, from about 1 to about 4 mEq/L potassium, from about 90 to about 120 mEq/L chloride, from about 3 to about 5 mEq/L acetate, from about 30 to about 40 mEq/L bicarbonate and from about 1 to about 250 µg/dl iron as an iron complex having a molecular weight of less than about 50,000.

As discussed above, in the field of dialysate preparation, it is common for dialysates to be prepared at the site of dialysis, immediately before or simultaneously with the dialysis procedure, by diluting a pre-made "dialysate concentrate" having dissolved therein the desired solutes at a very high concentration. In this regard, dialysate concentrates, which are also considered to be a part of the present invention, are typically prepared such that the solutes have concentrations about 30-40 times greater than the desired concentration in the actual dialysate fluid, e.g. the preferred concentrations given above. The present inventor has discovered that certain iron complexes of the

invention, such as, for example, ferrous gluconate, have excellent solubility and may find advantageous use in the preparation of dialysate concentrates.

In this respect, in another aspect of the invention, there is provided a dialysate concentrate comprising sodium, magnesium, calcium, potassium, chloride, acetate, bicarbonate and an iron complex having a molecular weight of less than about 50,000. In certain preferred embodiments of the invention, the concentrate may also optionally include dextrose, a sorbent and/or a surfactant. As stated above, the concentrate may then be diluted to the desired dialysate concentration, preferably in the dialysis apparatus itself, and the ratio of concentrate to diluent combined in the dilution apparatus may be carefully controlled to achieve the desired concentrations of materials dissolved in the dialysate. More preferably, the concentrate comprises the above compositions at concentrations from about 35 to about 45 times more concentrated than the desired dialysate concentration, even more preferably between about 34 and about 38 times more concentrated and, most preferably from about 35 to about 37 times more concentrated.

In a preferred aspect of the invention, the iron complex which is dissolved into a dialysate or a dialysate concentrate is ferrous gluconate. Ferrous gluconate is commercially available from Fluka Chemical Corporation, Chemika--Biochemika,

980 South Second Street, Ronkonkoma, New York, New York
11779-7238. Ferrous gluconate has been found by the present
inventor to be extremely soluble and to readily diffuse into
blood through a dialysis membrane during conventional
hemodialysis techniques. In this iron complex, two gluconate
anions are tightly complexed with a ferrous ion in the presence
of water.

Furthermore, as is demonstrated in Example 1, ferrous
gluconate surprisingly transfers into blood from dialysate in
an amount substantially higher than that expected based upon
the level of transferrin in the blood. Normally, it is
expected that blood plasma is able to bind no more iron than
that held by transferrin, which is the main iron binding
protein in the blood. However, in the experiment set forth in
Example 1, a ferrous gluconate concentration (125 μ /dl) was
purposely provided in the dialysate which was less than the
transferrin iron binding capacity (225 μ g/dl) in the blood.
As is shown in Fig. 1, after only a few minutes of
hemodialysis, the transferrin iron level of the blood was
reached, and the percent saturation of this iron protein was
100%. Nevertheless, the iron level in the plasma continued to
rise over the next half hour or more of dialysis to a level in
the plasma which was several times higher than the fully
saturated transferrin level, and also much higher than the
level of iron in the dialysate (125 μ g/dl).

While it is not intended that the present invention be limited by any mechanism by which it achieves its advantageous result, it appears that ferrous gluconate complexes are bound by another protein in the blood. The mechanism by which this occurs is not known; however, it is evident that the invention enables the delivery of iron complexes from dialysate into blood to much higher levels than previously considered possible. Furthermore, since this iron complex does not become dissolved in blood plasma, there should be much less threat of toxicity caused by increasing free iron levels in the blood. While this result was achieved by delivering ferrous gluconate to blood from dialysate, it is expected that a wide variety of compositions having similar characteristics to ferrous gluconate would show similar results according to the present invention.

The invention will be further described with reference to the following specific Examples and associated Figures. It will be understood that these Examples are illustrative and not restrictive in nature.

EXAMPLE ONE

TRANSFER OF FERROUS GLUCONATE INTO BLOOD

A two liter volume of bovine blood (hematocrit adjusted from 49 to 40 with saline) which had been stored with heparin anticoagulation for 24 hours was dialyzed using a PAN membrane

dialyzer. The volume was maintained at 2 liters throughout the experiment by adding saline. The dialyzer type was FILTRAL 12 and the PAN membranes used had an intrinsic negative charge and, therefore, tended to bind positively charged molecules. The dialysate was created from 20 liters of purified (deionized) water with acetate concentrate (Dial Medical Supply Concentrate Solution for Acetate Dialysate) in a 1:34 dilution with water and 10 mg/L ferrous gluconate (1 mg/dl containing 125 µg/dl iron).

A sample of the blood was taken prior to dialysis of the blood and tested for iron content. The iron content of the pre-dialysis blood was 110 µg/dl and the transferrin iron binding capacity was 225 µg/dl. Dialysis was then started using the following equipment and conditions:

Blood Pump:	Minipump Renal Systems at 300 ml/min (setting 323, 1/4")
Dialysate Pump:	Travenol at 500 ml/min (setting approximately 92)
Bath for Dialysate:	37°C

The circuit was primed with dialysate, prepared as described above, pumps were adjusted for proper flow, and then the blood side was drained of dialysate by pulling the Blood In tube out of the dialysis bath and allowing air to fill this side.

Assays were performed to determine plasma iron concentrations at 0, 5, 10, 20 and 30 minutes. A plot of iron concentration in plasma versus elapsed time of this experiment is provided in Fig. 1. Though the iron content of the dialysate was only 125 $\mu\text{g}/\text{dl}$, it was found that a continued transfer of iron into the blood proceeded until the plasma level reached nearly 500 $\mu\text{g}/\text{dl}$ after 30 minutes. This transfer indicates an avidity of plasma for the iron complex, even higher than the iron binding capacity of transferrin.

Based upon these results, it is concluded that if the initial rate of iron transfer to the plasma is continued according to this experiment for a period of 180 minutes, approximately 4 mg of iron would be transferred to the plasma. Therefore, to transfer 15 mg of iron to the patient during dialysis, the iron concentration in the dialysate would need to be increased four-fold. As such, increasing the dialysate concentration of ferrous gluconate to 4 mg/dl (with iron concentration of 0.5 $\mu\text{g}/\text{dl}$) will result in transfer of 15 mg of iron per dialysis treatment.

EXAMPLE TWO

MONITORING OF HEMOLYSIS IN EXPERIMENTAL DIALYSIS

To determine whether the method of Example 1 would cause hemolysis (lysis of red blood cells with the liberation of hemoglobin), absorbance data at 420 and 585 nm was collected

for the plasma at various stages of the experiment described in Example 1. These data are provided in Fig. 2. The increase in absorbance indicates that some degree of hemolysis occurred during the experiment; however, this level is not higher than that of similar experiments conducted without iron in the dialysate.

EXAMPLE THREE

EFFECT ON BLOOD-LEAK DETECTION SYSTEMS

To determine whether the presence of ferrous gluconate in the dialysate would interfere with blood-leak detection systems used in hemodialysis procedures, optical absorbance data for ferrous gluconate at high concentrations were obtained. These data are provided in Fig. 3. From the plot of Fig. 3, it is apparent that iron can be added to the dialysate without interfering with the detection of hemoglobin in dialysate by blood-leak detectors using optical absorbance at either 420 nm or 585 nm.

While the invention has been described in detail in the foregoing description, the same is to be considered as illustrative and not restrictive in character, it being understood that only the preferred embodiments have been described and that all changes and modifications that come within the spirit of the invention are desired to be protected.

What is claimed is:

1. A method for delivering iron to blood comprising:
providing a dialysate having dissolved therein a complex of
one or more divalent or trivalent iron ions and one or more
anions, the complex having a molecular weight of less than
about 50,000; and

dialyzing a patient with the dialysate to increase the
level of iron in the patient's blood.

2. The method according to claim 1, wherein the anion is
an organic anion.

3. The method according to claim 1, wherein the molecular
weight is less than about 12,000; and wherein said dialyzing
comprises dialyzing the blood extracorporeally with the
dialysate.

4. The method according to claim 1, wherein said
dialyzing comprises introducing the dialysate into the
patient's peritoneum.

5. A method for delivering iron to a patient with the
introduction of substantially no free iron into the patient's
blood, comprising:

providing a dialysate composition having dissolved therein a complex of one or more multi-polar, divalent or trivalent iron ions and one or more anions having a molecular weight of less than about 50,000; and

performing dialysis on a patient with the dialysate.

6. The method according to claim 5, wherein the concentration of divalent or trivalent iron ions in the dialysate is at least about 50µg/dl and the molecular weight of the complex is less than about 25,000.

7. The method according to claim 5, wherein the anion is an organic anion.

8. The method according to claim 7, wherein the organic anion has a molecular weight of less than about 12,000.

9. The method according to claim 8, wherein the complex is ferrous gluconate.

10. A method for delivering iron to blood, comprising:
passing blood against a first side of a membrane; and
passing against a second side of the membrane an aqueous solution having dissolved therein an iron complex comprising one or more iron ions and one or more anions; the complex having a molecular weight of less than about 12,000;

wherein the membrane is permeable to the complex; and
wherein the complex is delivered to the blood.

11. The method according to claim 10, wherein the complex has a molecular weight of less than about 5,000.

12. The method according to claim 10, wherein the complex is ferrous gluconate.

13. A method for delivering iron to a patient, comprising:
introducing a dialysate into a patient's peritoneal cavity,
the dialysate having dissolved therein a complex of one or more
divalent or trivalent iron ions and one or more anions;

wherein the complex has a molecular weight of less than
about 50,000.

14. The method according to claim 13, wherein the complex has a molecular weight of less than about 25,000.

15. The method according to claim 13, wherein the anion is an organic anion.

16. A method for the treatment of a patient to increase the level of iron in the patient's bloodstream, which comprises performing dialysis on the patient with a dialysate which

comprises a soluble, low molecular weight iron complex; sodium; magnesium; calcium; potassium; chloride; acetate and bicarbonate.

17. A method for delivering iron to blood comprising:
dialyzing a patient with a dialysate having dissolved therein a complex of one or more divalent or trivalent iron ions and one or more anions having a molecular weight of less than about 50,000 to increase the level of iron in the patient's blood.

18. A dialysate composition comprising an aqueous medium having dissolved therein sodium, magnesium, calcium, potassium, chloride, acetate, bicarbonate and an iron complex having a molecular weight of less than about 50,000.

19. The dialysate composition according to claim 18, further comprising a member selected from the group consisting of dextrose, a sorbent and a surfactant. →

20. The dialysate composition according to claim 18, comprising from about 130 to about 150 mEq/L sodium, from about 0.4 to about 1.5 mEq/L magnesium, from about 2 to about 4 mEq/L calcium, from about 1 to about 3 mEq/L potassium, from about 90 to about 120 mEq/L chloride, from about 3 to

about 5 mEq/L acetate, from about 30 to about 40 mEq/L bicarbonate and from about 1 to about 250 µg/dl iron as an iron complex having a molecular weight of less than about 50,000.

21. A dialysate concentrate comprising an aqueous medium having dissolved therein sodium, magnesium, calcium, potassium, chloride, acetate, bicarbonate and an iron complex having a molecular weight of less than about 50,000.

22. The dialysate concentrate according to claim 21, further comprising a member selected from the group consisting of dextrose, a sorbent and a surfactant.

23. The dialysate concentrate according to claim 21, wherein the concentrate may be diluted to provide a dialysate; and wherein the sodium, magnesium, calcium, potassium, chloride, acetate, bicarbonate and iron complex are present in the concentrate at concentrations from about 30 to about 40 times higher than their concentrations in the dialysate.

ABSTRACT OF THE DISCLOSURE

The invention relates to methods and compositions for delivering iron to an iron-deficient patient, more particularly, to methods whereby an iron complex comprising divalent or trivalent ionic iron complexed with one or more low molecular weight anions is administered to a patient by transfer from dialysate. A complex selected according to the invention is non-polymeric; soluble in an aqueous medium; chemically stable, thereby preventing the dissociation of iron ions from the anions under conditions according to the invention; and can be well absorbed into blood and the living body. Also provided are dialysate compositions including therein an iron complex selected according to the invention, and dialysate concentrates which may be diluted to yield an inventive dialysate composition.




Fig. 1




Fig. 2




Fig. 3

Docket No.

11002-29

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

METHOD FOR IRON DELIVERY TO A PATIENT BY TRANSFER FROM DIALYSATE

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on June 5, 1997 as United States Application No. or PCT International

~~Application Number~~ 08/869,331

and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

<u>60/023,926</u>	<u>August 14, 1996</u>
(Application Serial No.)	(Filing Date)

_____	_____
(Application Serial No.)	(Filing Date)

_____	_____
(Application Serial No.)	(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

Harold R. Woodard 16,214; C. David Emhardt 18,483; Holiday W. Banta 40,311; Troy J. Cole 35,102; L. Scott Joseph A. Naughton 19814; John V. Moriarty 26,207; Paynter 39,797; J. Andrew Lowes P40,706; Matthew R. John C. McNett 25,533; Thomas Q. Henry 28,309; James Schantz P40,800; Gregory B. Coy P40,967; Lisa Hiday M. Durlacher 28,840; Charles R. Reeves 28,750; Vincent 40,036; John V. Daniluck P40,581 O. Wagner 29,596; Steve Zlatos 30,123, Spiro Bereveskos 30,821; William F. Bahret 31,087; Clifford W. Browning 32,201; R. Randall Frisk 32,221; Daniel J. Lueders 32,581; Michael D. Beck 32,722; Kenneth A. Gandy 33,386; Timothy N. Thomas 35,714; Kerry P. Sisselman 37,237; Kurt N. Jones 37,996; John H. Allie 39,088; Jeffrey A. Michael 37,394; Deborah K. Knoll 37,370;

Send Correspondence to: Gregory B. Coy
Woodard, Emhardt, Naughton, Moriarty & McNett
111 Monument Circle, Suite 3700
Indianapolis, IN 46204

Direct Telephone Calls to: *(name and telephone number)*
317-634-3456

Full name of sole or first inventor	
Stephen R. Ash	
Sole or first inventor's	Date
	JUNE 26, 1997
Residence	
3736 Pershing Drive, Lafayette, Indiana 47905	
Citizenship	
USA	
Post Office Address	
3736 Pershing Drive, Lafayette, Indiana 47905	

Full name of second inventor, if any	
Second inventor's signature	Date
Residence	
Citizenship	
Post Office Address	